MMP-2 responsive polymeric micelles for cancer-targeted intracellular drug delivery

2015 ◽  
Vol 51 (3) ◽  
pp. 465-468 ◽  
Author(s):  
Wei-Hai Chen ◽  
Guo-Feng Luo ◽  
Qi Lei ◽  
Hui-Zhen Jia ◽  
Sheng Hong ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Cells ◽  
Polymeric Micelles ◽  
Intracellular Drug Delivery

Multifunctional Biotin-PEG-b-PLL(Mal)-peptide-DOX polymeric micelles were demonstrated to selectively eliminate cancer cells with significantly reduced side effects.

Mixed-Charged Zwitterionic Polymeric Micelles for Tumor Acidic Environment Responsive Intracellular Drug Delivery

Langmuir ◽  
2018 ◽  
Vol 35 (5) ◽  
pp. 1242-1248 ◽  
Author(s):  
Zhihui Qin ◽  
Tingting Chen ◽  
Wenzhuo Teng ◽  
Qiao Jin ◽  
Jian Ji
Keyword(s):  
Drug Delivery ◽  
Polymeric Micelles ◽  
Acidic Environment ◽  
Intracellular Drug Delivery

Biodegradable multiblock polyurethane micelles with tunable reduction-sensitivity for on-demand intracellular drug delivery

RSC Advances ◽  
2014 ◽  
Vol 4 (47) ◽  
pp. 24736-24746 ◽  
Author(s):  
Xueling He ◽  
Mingming Ding ◽  
Jiehua Li ◽  
Hong Tan ◽  
Qiang Fu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Tumor Cells ◽  
On Demand ◽  
Intracellular Drug Delivery ◽  
Disulfide Linkages ◽  
Drug Delivery Applications

Biodegradable polyurethanes bearing varied amounts of disulfide linkages in the backbone can rapidly enter tumor cells and efficiently transport the encapsulated payloads into cytosol, resulting in controlled inhibition effects against cancer cells. The nanocarriers are promising candidates for on-demand intracellular drug delivery applications.

Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature

2010 ◽  
Vol 19 (1) ◽  
pp. 25-36 ◽  
Author(s):  
Jie Yin ◽  
Zaiquan Li ◽  
Tingyuan Yang ◽  
Jiancheng Wang ◽  
Xuan Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Tumor Cells ◽  
Polymeric Micelles ◽  
Intracellular Drug Delivery

Combinatorial targeting polymeric micelles for anti-tumor drug delivery

2015 ◽  
Vol 3 (19) ◽  
pp. 4043-4051 ◽  
Author(s):  
Saina Yang ◽  
Feiyan Zhu ◽  
Qian Wang ◽  
Fuxin Liang ◽  
Xiaozhong Qu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Polymeric Micelles ◽  
Tumor Ph ◽  
Tumor Drug Delivery ◽  
Targeting Ability

Polymeric micelles with combinatorial targeting ability for cancer cells was achieved by co-assembly of cRGD-PEO-b-PCL and tumor pHesensitive PEG-DOX.

Freezing-Assisted Intracellular Drug Delivery to Multidrug Resistant Cancer Cells

2009 ◽  
Vol 131 (7) ◽  
Author(s):  
Ka Yaw Teo ◽  
Bumsoo Han
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Plasma Membranes ◽  
Cancer Cell Line ◽  
Multidrug Resistant ◽  
Drug Uptake ◽  
Freezing And Thawing ◽  
Intracellular Space ◽  
Intracellular Drug Delivery ◽  
Model Drug

The efficacy of chemotherapy is significantly impaired by the multidrug resistance (MDR) of cancer cells. The mechanism of MDR is associated with the overexpression of certain adenosine triphosphate-binding cassette protein transporters in plasma membranes, which actively pump out cytotoxic drugs from the intracellular space. In this study, we tested a hypothesis that freezing and thawing (F/T) may enhance intracellular drug delivery to MDR cancer cells via F/T-induced denaturation of MDR-associated proteins and/or membrane permeabilization. After a human MDR cancer cell line (NCI/ADR-RES) was exposed to several F/T conditions, its cellular drug uptake was quantified by a fluorescent calcein assay using calcein as a model drug. After F/T to −20°C, the intracellular uptake of calcein increased by 70.1% (n=5, P=0.0004). It further increased to 118% as NCI/ADR-RES cells were frozen/thawed to −40°C (n=3, P=0.009). These results support the hypothesis, and possible mechanisms of F/T-enhanced intracellular drug delivery were proposed and discussed.

scholarly journals Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review

2021 ◽  
Vol 22 (19) ◽  
pp. 10319
Author(s):  
Saman Sargazi ◽  
Mahwash Mukhtar ◽  
Abbas Rahdar ◽  
Mahmood Barani ◽  
Sadanad Pandey ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Dna Repair ◽  
Cancer Cells ◽  
Polymeric Micelles ◽  
Drug Carriers ◽  
Antioxidant Response ◽  
Parp Inhibitors ◽  
Preliminary Review ◽  
Repair Gene ◽  
Dna Repair Gene

Nanotechnology has revolutionized novel drug delivery strategies through establishing nanoscale drug carriers, such as niosomes, liposomes, nanomicelles, dendrimers, polymeric micelles, and nanoparticles (NPs). Owing to their desirable cancer-targeting efficacy and controlled release, these nanotherapeutic modalities are broadly used in clinics to improve the efficacy of small-molecule inhibitors. Poly(ADP-ribose) polymerase (PARP) family members engage in various intracellular processes, including DNA repair, gene transcription, signal transduction, cell cycle regulation, cell division, and antioxidant response. PARP inhibitors are synthetic small-molecules that have emerged as one of the most successful innovative strategies for targeted therapy in cancer cells harboring mutations in DNA repair genes. Despite these advances, drug resistance and unwanted side effects are two significant drawbacks to using PARP inhibitors in the clinic. Recently, the development of practical nanotechnology-based drug delivery systems has tremendously improved the efficacy of PARP inhibitors. NPs can specifically accumulate in the leaky vasculature of the tumor and cancer cells and release the chemotherapeutic moiety in the tumor microenvironment. On the contrary, NPs are usually unable to permeate across the body’s normal organs and tissues; hence the toxicity is zero to none. NPs can modify the release of encapsulated drugs based on the composition of the coating substance. Delivering PARP inhibitors without modulation often leads to the toxic effect; therefore, a delivery vehicle is essential to encapsulate them. Various nanocarriers have been exploited to deliver PARP inhibitors in different cancers. Through this review, we hope to cast light on the most innovative advances in applying PARP inhibitors for therapeutic purposes.

RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells

2014 ◽  
Vol 87 (3) ◽  
pp. 489-499 ◽  
Author(s):  
Min Hyung Kang ◽  
Min Jung Park ◽  
Hyun Joon Yoo ◽  
Kwon Yie hyuk ◽  
Sang Gon Lee ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Intracellular Drug Delivery
Sign in / Sign up

Export Citation Format

Share Document